Happy CD3 CD28 T Cell Stimulation Day to all who celebrate

A bit of a #HumbleBrag The Hans Messner AlloBMT program @hansbmt.bsky.social just infused the 200th allograft of this fiscal year. A new record for us and for Canada! #bmtsm @tomam04.bsky.social @nihardesai7.bsky.social @uhnresearch.bsky.social

Out now in Blood Advances 🙌🏽 Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation! Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽 ashpublications.org/bloodadvance...

#ASH24 #leusm Eissa: real world data re FLT3i maintenance post-allo. 171 with, 269 wo maintenance. Most received sorafenib.

#ASH24 #leusm Eissa: no diff between sorafenib vs gilt. Unfortunately, no pre-HCT MRD data to compare these data directly with BMT-CTN 1506/MORPHO.

This year at #ASH24 the team at @hansbmt.bsky.social are presenting 2 Oral Abstracts and 9 Posters! While many of us are not attending in person this year please connect with @nihardesai7.bsky.social who is on site and will talk your ear off about the cool stuff we do here!

📢 Out in the European Journal of Hematology 🙌🏼 Red cell aplasia is uncommon but causes significant morbidity 😭 Daratumumab is effective, well tolerated, and leads to rapid and sustained responses 💪🏼 doi.org/10.1111/ejh....

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky